Ran on 06 Apr 2026
Management delivered on 2 of 5 commitments (40% hit rate). Key misses: Capex to Revenue Ratio (Revised), Other Findings (Missed).
| Metric | Commentary | Source |
|---|---|---|
Production Capacity Target: 360 KT | The company plans to scale up MMA capacities from 290+ KT to 360 KT by the end of FY26. | Concall Feb 2026 p.4 |
Project Commissioning Target: Commissioning of MPP and Chloro toluene blocks | Management expects to commission the MPP, Chloro toluene, and downstream process blocks in Zone 4 during the current calendar year. | Concall Feb 2026 p.4 |
CAPEX Target: Rs. 1,100 crs | Total CAPEX for the current year is estimated at Rs. 1,100 crore, an increase from the previous guidance of Rs. 1,000 crore. | Concall Feb 2026 p.4 |
Project Commissioning Target: Commissioning | The Joint Venture with Superform is expected to be commissioned in Q1FY27. | Concall Feb 2026 p.5 |
Project Commissioning Target: Commissioning | The Joint Venture with RESL is planned for commissioning in the first half of FY27. | Concall Feb 2026 p.5 |
Portfolio Mix Target: 30% to 40% | Management targets MMA to settle between 30% to 40% of the total product portfolio over the medium term. | Concall Feb 2026 p.6 |
“Total CAPEX for FY26 is expected to be approximately Rs. 1,000 crore.”
“FY26 capex to be ~₹1100 crs, v/s initially planned capex of ₹1000 crs.”
The company is maintaining its heavy investment cycle through FY26, with Q2 and Q3 FY26 earnings calls focusing on the execution of the ~₹1,100 crore capex plan.
Aarti Industries Limited (AARTIIND.BO) - Yahoo Finance“Management expects to reduce net debt by Rs. 200 to 300 crore in FY26.”
“Working capital increased due to increase in exports, resulting in higher debt and finance costs.”
Aarti Industries maintains a significant weight (2.70%) in emerging opportunity funds, reflecting institutional confidence in management's long-term targets.
L&T Emerging Opportunities Fund - Series II ... - Yahoo Finance“Technology finalisation for the plastic recycling JV is targeted for Q1 FY26.”
“EC Approval obtained. Delivery for critical equipment for plant setup underway.”
The Re Aarti JV for chemical recycling of plastics is progressing toward its early FY27 commercial operations target.
Aarti Industries Limited (AARTIIND.BO) Stock Price, News, Quote ...“Commissioning of the Calcium Chloride facility in the ongoing quarter (Q3 FY26).”
“Commissioning within Q3 FY26”
Management reported strong revenue growth in Q3 FY26, indicating that the ramp-up of newly commissioned capacities is beginning to reflect in the top line.
Aarti Industries Limited (AARTIIND.NS) - Yahoo Finance| Metric | Promise | Actual | Status | Source |
|---|---|---|---|---|
New Capacity Q3 FY26 | Commissioning of the Calcium Chloride facility in the ongoing quarter (Q3 FY26). | Commissioning within Q3 FY26 | Met | Concall Feb 2026 p.10 Concall Nov 2025 p.5 |
CAPEX Q3 FY26 | Total CAPEX for FY26 is expected to be approximately Rs. 1,000 crore. | FY26 capex to be ~₹1100 crs, v/s initially planned capex of ₹1000 crs. | Revised | PPT Feb 2026 p.10 Concall Nov 2025 p.3 |
New Capacity Q3 FY26 | Commissioning of the Calcium Chloride facility in the ongoing quarter (Q3 FY26). | Zone 4 Calcium Chloride plant under final trials and to be commercialised soon | Revised | PPT Feb 2026 p.13 Concall Nov 2025 p.5 |
Production Capacity Q3 FY26 | The MMA capacity expansion to 260 kT is completed and will contribute from Q1 FY26. | MMA Capacity: 290+ KTPA; Q3 FY26 Production: 69.0 kT (96% utilization) | Exceeded | PPT Feb 2026 p.11 PPT Aug 2025 p.11 |
Strategic Milestone Q3 FY26 | Technology finalisation for the plastic recycling JV is targeted for Q1 FY26. | EC Approval obtained. Delivery for critical equipment for plant setup underway. | Met | PPT Feb 2026 p.15 PPT May 2025 p.15 |
Project Commissioning Q3 FY26 | The chlorotoluene project is expected to be commissioned in the second half of FY26. | CaCl2 chemical charging started; MPP commissioning expected in Q4 FY26 | In Progress | PPT Feb 2026 p.9 Concall May 2025 p.13 |
Net Debt Reduction Q3 FY26 | Management expects to reduce net debt by Rs. 200 to 300 crore in FY26. | Working capital increased due to increase in exports, resulting in higher debt and finance costs. | Missed | PPT Feb 2026 p.10 Concall Aug 2025 p.17 |
Aarti Industries is a major Indian chemical company that transforms basic chemicals into high-value ingredients used in everyday products. They primarily serve the energy, agrochemical (farming), and pharmaceutical (medicine) industries by mastering complex chemical processes. The company makes money by selling these specialized chemical building blocks to global manufacturers, with a significant portion of their business coming from international exports.
8 engines · 2 moats (2 strong) · 2 geographies ·The segment share has expanded from 12% to 18% of total revenue, though management notes that pricing remains under pressure globally. (1 expanding, 1 stable, 1 shifted, 1 contracting across 1 engine)
Agrochemicals & Fertilizers
The Agrochemicals & Fertilizers segment is seeing a steady recovery in volume, though profit margins remain under pressure due to global competition.
The segment share has expanded from 12% to 18% of total revenue, though management notes that pricing remains under pressure globally.
The Agrochemicals and Pharmaceuticals segments (21% combined share) are facing structural margin pressure due to aggressive pricing and 'dumping' from Chinese manufacturers. This oversupply from China forces Aarti to lower prices to maintain market share, eroding the profitability of these segments.
Aarti Industries Limited (AARTIIND.NS) - Yahoo FinanceExports reached an all-time high of 65% of total revenue, driven by a resumption of US volumes and diversification into Europe and the Middle East. (2 expanding, 3 contracting)
Exports reached a record high this quarter, accounting for nearly two-thirds of the company's total sales, driven by a strategy to diversify away from over-reliance on any single international market.
Exports reached an all-time high of 65% of total revenue, driven by a resumption of US volumes and diversification into Europe and the Middle East.
With exports reaching nearly two-thirds of total sales, Aarti is highly exposed to global logistics disruptions and currency fluctuations. While diversification reduces reliance on one market, structural shifts in global trade policies could impact the company's competitive pricing abroad.
Aarti Industries Limited (AARTIIND.NS) - Yahoo FinanceThe Energy segment continues to be a high-growth driver, posting 21% sequential volume growth as the company diversifies its customer base and geographical reach. (1 expanding, 2 contracting across 2 engines)
Energy
The Energy segment is the largest revenue contributor, driven by high demand for fuel blending and expanded production capacity.
The Energy segment continues to be a high-growth driver, posting 21% sequential volume growth as the company diversifies its customer base and geographical reach.
Aarti Industries' market capitalization and financial performance are subject to broader materials sector volatility in India. Competitive pricing by domestic peers who are also expanding capacity could lead to a 'race to the bottom' on margins for commodity-like specialty chemicals.
Aarti Industries Limited (AARTIIND.NS) - Yahoo FinanceEnergy business (MMA)
↑ GrowingThe Energy business, led by the product MMA, is the company's primary growth engine. It currently benefits from robust volumes and favorable pricing spreads between raw materials and finished products.
“The energy business, led by MMA, continued to remain a key growth driver. Volumes have been robust, supported by strong demand and favourable feedstock spreads.”
Agrochemicals and Pharmaceuticals
→ Stable12%
The Agrochemicals and Pharmaceuticals segments are seeing stable sales volumes, though profits are currently squeezed because of low-priced competition (dumping) from China.
“Agrochemicals and Pharmaceuticals continue to see stable volumes, but pricing remained subdued due to persistent dumping by China. ... currently, we are standing at 12% of overall top line in agro on a quarterly basis.”
While volumes are stable, pricing remains under pressure due to Chinese dumping; however, management expects margin recovery as China shifts its 'anti-involution' strategy and removes VAT subsidies.
Agrochemical volumes are showing promising recovery, and the segment's share is expected to 'inch up' as new projects like PEDA (4,000 TPA) are commissioned.
Agrochemical intermediates continue to face significant pricing pressure, while pharmaceutical applications remain stable.
The Pharma segment share has slightly decreased, but management expects positive developments from H1-FY26 due to domestic market share gains.
The segment is experiencing a volume-led recovery with 14% sequential growth, though pricing remains under pressure due to Chinese overcapacity and marginal pricing strategies.
Polymers
↑ GrowingThe Polymers segment is experiencing mixed results; while demand for certain chemicals used in Electric Vehicles (EVs) is rising, other products dependent on the US market have faced pricing pressure.
“The Polymers’ segment had a mixed business environment. PDCB demand saw an uptick driven by PPS growth in the EV segment while PDA product chains continued to face volume and pricing pressure”
Energy
↑ Growing (78% YoY (Volume))51%
The Energy segment is the largest revenue contributor, driven by high demand for fuel blending and expanded production capacity.
“Energy... 51%... Higher volumes in energy application driven by favorable blending economics, expanded capacities and increasing opportunities in newer geographies.”
The Energy segment, led by MMA, remains the primary growth engine with robust volumes and favorable feedstock spreads. Capacity is being expanded from 290+ KT to 360 KT by Q4FY26 to meet demand.
The Energy segment continues to be the primary growth engine, with volumes expanding significantly due to favorable blending economics and capacity ramp-up.
The energy-linked portfolio (MMA) achieved highest-ever quarterly volumes, though its revenue share is expected to normalize to 30-40% as other segments ramp up.
The Energy segment has seen massive expansion, now contributing 43% of total revenue compared to 36% in FY25, driven by favorable blending economics and a 118% YoY volume increase in energy products.
The Energy segment's revenue share decreased from 51% to 36% of total revenue, although it remains the largest single end-use category. Management noted that while volumes are higher, margins are under pressure due to pricing dynamics.
The Energy segment (MMA) saw volumes remain flattish due to plant disruptions and Indo-Pak conflict, but the company successfully expanded capacity from 200 KTPA to 260 KTPA to maintain global leadership.
The Energy segment remains the largest revenue contributor but is experiencing margin compression due to pricing pressures, despite volume growth.
The Energy segment continues to be a high-growth driver, posting 21% sequential volume growth as the company diversifies its customer base and geographical reach.
Polymer and Additives
↑ Growing14%
The Polymer and Additives segment contributes significantly to revenue, with growth supported by the resumption of exports to the US and demand from the Electric Vehicle (EV) sector.
“Polymer and additives... Revenue Share 14%... EV application driving strong growth for PDCB required for polymer application”
The segment shows mixed results; PDCB is expanding due to EV-driven demand for PPS, while PDA faces pressure but is expected to recover following the US-India trade deal.
The segment is seeing a recovery in US export volumes following tariff-related disruptions, though its overall revenue share has dipped slightly compared to the previous quarter.
The polymer business faced significant headwinds this quarter specifically due to the impact of U.S. tariffs on volumes.
The segment's revenue share contracted to 12% as volumes were negatively impacted by US tariffs on key end-use applications like Dyes and Polymers.
The segment showed mixed performance; while some areas recovered, DCB (Dichlorobenzene) volumes declined significantly due to inventory liquidation by US automotive customers.
The segment is on a recovery path with a slight increase in revenue share, supported by strong export traction to the USA.
The segment is facing temporary pressure in the Dichlorobenzene (DCB) chain due to inventory correction in the automotive (PPS) sector in the US and Japan.
Agrochemicals & Fertilizers
→ Stable12%
The Agrochemicals & Fertilizers segment is seeing a steady recovery in volume, though profit margins remain under pressure due to global competition.
“Agrochemical & Fertilizers... Revenue Share 12%... Agrochemicals application showing steady volume recovery; margins remained under pressure”
While volumes are showing a steady recovery, the segment's share of total revenue has contracted, and margins remain under pressure from Chinese competition.
Revenue share for Agrochemicals has increased slightly to 19%, but the segment continues to face significant margin pressure from Chinese competition and evolving US tariffs.
The segment's revenue share increased from 12% to 18% for the full year FY25, showing a recovery in contribution despite management noting that intermediates for this sector remain under pricing pressure.
The segment share has expanded from 12% to 18% of total revenue, though management notes that pricing remains under pressure globally.
Dyes, Pigments and Printing Inks
→ Stable11%
The Dyes, Pigments and Printing Inks segment maintains a stable share of the business despite pricing pressures in the market.
“Dyes, Pigments & Printing Inks... Revenue Share 11%... Pricing pressure continues to prevail”
Pharmaceuticals
→ Stable9%
The Pharmaceuticals segment serves the steady domestic Indian market, focusing on advanced chemical compounds for drug manufacturing.
“Pharmaceuticals... Revenue Share 9%... India’s domestic pharma market remains steady”
| # | Dimension | Score | Trend | Key Evidence | |
|---|---|---|---|---|---|
1 | IP / Technology | 9/10 | Stable | Aarti possesses significant technical moats through its mastery of complex chemical reactions (chemi... | |
Aarti possesses significant technical moats through its mastery of complex chemical reactions (chemistries) and its 200+ product portfolio developed in-house. “Strong R&D capabilities with IPRs for customized products... 2 State-of-the art R&D Centers” Investor PPT • Feb 2026 • p.6 Trend Evidence Q3 FY26 Aarti is pivoting toward 'Advanced Materials' and high-value application-led solutions, leveraging in-house R&D and indigenous technology for its new Zone 4 projects. Concall Transcript • Feb 2026 • p.4 Q2 FY26 Aarti is shifting from a heavy CAPEX cycle to an innovation-led growth phase, focusing on R&D for advanced materials and CDMO (Contract Development and Manufacturing) projects. Concall Transcript • Nov 2025 • p.5 Q1 FY26 Aarti is expanding its technical moat by entering 'Zone IV' with 15-20 new high-value products and advanced chemistries targeted for H2 FY26. Concall Transcript • Aug 2025 • p.7 Q4 FY25 Aarti is shifting its technical moat toward 'New Growth Avenues' including battery materials and sustainability platforms. Investor PPT • May 2025 • p.19 Aarti is expanding its technical moat by commissioning a new pilot plant at Zone IV to drive innovation and diversify its product offerings into new chemistries. Concall Transcript • May 2025 • p.4 | |||||
2 | Cost Advantage | 8/10 | Widening | The company maintains a deep competitive advantage through its 'Integrated Operations,' where the wa... | |
The company maintains a deep competitive advantage through its 'Integrated Operations,' where the waste or byproduct of one process becomes the raw material for the next, significantly lowering costs. “Integrated operations and high-cost optimization... Key value chains include Nitro Chloro Benzenes, Di-Chlorobenzenes, Phenylenediamines” Investor PPT • Feb 2026 • p.6 Trend Evidence Q3 FY26 The company is enhancing its cost moat through the deployment of AI and digital transformation tools for real-time process control and predictive maintenance. Concall Transcript • Feb 2026 • p.4 The company is intensifying its cost-saving initiatives, targeting a specific EBITDA contribution from cost optimization through energy efficiency and yield improvements. Investor PPT • Feb 2026 • p.17 Q2 FY26 Aarti is strengthening its cost moat through a new long-term chlorine supply agreement with DCM Shriram, involving a dedicated pipeline to ensure supply security and cost efficiency for its upcoming Zone-IV facility. Investor PPT • Nov 2025 • p.10 Q1 FY26 The company is aggressively expanding its cost moat through specific efficiency projects like the Back-Pressure Turbine (BPT) and Hybrid Power, aiming for an additional Rs 150-200 Cr in EBITDA from cost optimization alone by FY28. Investor PPT • Aug 2025 • p.11 The company is aggressively implementing new cost-saving initiatives, including renewable power and yield improvements, to protect margins against falling raw material prices. Concall Transcript • Aug 2025 • p.14 Q4 FY25 The company is aggressively expanding its cost moat through a dedicated 'Cost Optimisation' program targeting Rs 150-200 Cr in EBITDA impact. Investor PPT • May 2025 • p.17 The company is intensifying its cost moat through new renewable energy agreements and specific yield improvement projects in Ammonolysis and Hydrogenation to offset global pricing pressures. Concall Transcript • May 2025 • p.4 | |||||
Exports
↑ GrowingShare → Stable65%
Exports reached a record high this quarter, accounting for nearly two-thirds of the company's total sales, driven by a strategy to diversify away from over-reliance on any single international market.
“Exports for the period constituted about 65% of the total revenues for the company, the highest both in terms of percentage share and also in absolute basis.”
Exports reached an all-time high of 65% of total revenue, driven by a resumption of US volumes and diversification into Europe and the Middle East.
Export volumes for key products like MMA and PDCB have resumed to the US, supporting the company's global footprint despite ongoing tariff challenges.
Export share remains high at over 60%, but the company is aggressively diversifying its geographic mix away from the U.S. toward Europe and the Middle East due to new U.S. tariffs.
The export mix has shifted significantly by application; while Energy exports are dominant (93%), other segments like Agrochemicals (36%) and Pharma (18%) show a higher reliance on the domestic Indian market.
Export revenue share has decreased from 65% to 54% (calculated as 100% minus 46% India share). However, the company reported substantial growth in absolute export volumes during the year.
Export share has decreased slightly to approximately 51% of total revenue (Rs. 950 crore out of Rs. 1,867 crore) due to geopolitical disruptions and deferred shipments.
Export share remains dominant but has shifted slightly downward from the previous record high of 65% to a weighted average across segments (e.g., 61% in Agro, 80% in Energy, 92% in Polymers).
Export share has decreased slightly from the previously noted 65% to 55% of revenue this quarter, though it remains a dominant part of the business with significant sequential volume improvement.
India (Domestic)
→ StableShare ↑ Growing35%
Domestic sales in India make up the remaining portion of the revenue, with the company expecting to replace imports from China with their own locally produced chemicals.
“Exports for the period constituted about 65% of the total revenues for the company [Implied domestic 35%]”
Domestic revenue share expanded significantly from 35% to 46%, indicating a stronger reliance on the home market and successful import substitution strategies.
Global pharmaceutical companies are increasingly looking to diversify their supply chains away from China (China + 1 strategy), benefiting Aarti's Pharmaceuticals segment (9% share). This shift in customer behavior toward Indian sourcing provides a long-term tailwind for advanced chemical intermediates. (Aarti Industries Limited (AARTIIND.NS) - Yahoo Finance)
Aarti Industries Limited (AARTIIND.NS) - Yahoo FinanceThe company is increasing its total capital expenditure for the 2026 fiscal year to fund growth projects like MMA and PEDA.
Capex has been revised upward from Rs. 1,000 crs to Rs. 1,100 crs to fast-track high-return projects like MMA and DCB debottlenecking.
A significant reduction in U.S. import taxes (tariffs) on Indian chemicals is expected to boost sales volumes and profits for products sold to the American market.
U.S. tariffs caused a significant volume drop in Q2, but management expects a resumption of volumes in Q3 despite ongoing uncertainty.
Export Revenue Share
Export revenues reached an all-time high, showing strong global demand for the company's products despite international trade challenges.
Export share has reached a record high of 65%, showing an accelerating trend in global market penetration despite geopolitical volatility.
Export volumes are recovering, particularly in the Energy and Polymer segments, with 85% of Energy and 92% of Polymer/Additives revenue coming from exports.
Export share remains high at upwards of 60%, though the company is actively rebalancing the mix away from the U.S. toward Europe and the Middle East due to tariff headwinds.
Export volumes grew by approximately 17% in FY25, indicating strong global traction and successful positioning in international markets.
Export revenue faced temporary headwinds from geopolitical conflicts (Israel-Iran and India-Pak) and logistics delays, leading to a deferment of Rs. 15-20 crore EBITDA to Q2.
Export traction is accelerating in specific segments like Energy & Additives (80% export) and Polymer & Additives (92% export), with a focus on diversifying the geographic base.
Export share is accelerating, reaching 55% in the most recent quarter, driven by a recovery in global shipments and strategic diversification into the US and Europe.
“Exports for the period constituted about 65% of the total revenues for the company, the highest both in terms of percentage share and also in absolute basis.”
U.S. Export Volume
A significant reduction in U.S. import taxes (tariffs) on Indian chemicals is expected to boost sales volumes and profits for products sold to the American market.
The US-India trade deal is a major positive inflection point, reversing the headwind of high tariffs and expected to significantly improve margins and volumes.
US export volumes for key products like MMA and PDCB have resumed in Q3 FY26, though full recovery remains linked to future trade deals.
U.S. tariffs caused a significant volume drop in Q2, but management expects a resumption of volumes in Q3 despite ongoing uncertainty.
US tariffs are currently a significant headwind, negatively impacting volumes in the PDA and Polymer/Additives segments. Recovery is explicitly linked to a potential US-India trade deal.
The US tariff actions against China are creating an immediate positive tailwind for specific chains like PDA (MPD), leading to higher anticipated utilization.
“given the reduction at an overall level is going to be quite significant from 50% plus to now 18% plus, there will be a margin that will accrue to all players in the value chain.”
Incremental capex for MMA expansions, PEDA, etc
The company is increasing its total capital expenditure for the 2026 fiscal year to fund growth projects like MMA and PEDA.
Capex has been revised upward from Rs. 1,000 crs to Rs. 1,100 crs to fast-track high-return projects like MMA and DCB debottlenecking.
Capex intensity is accelerating as the company increases its FY26 budget to Rs. 1100 crore to fast-track MMA and PEDA expansions.
The company is maintaining its FY26 capex guidance of Rs. 1,000 crore but signals a significant reduction in spending for FY27 as the current cycle concludes.
Capex remains aggressive at approximately Rs. 1000 Cr for FY26 to drive the next 3 years of volume growth. This represents a high investment intensity to reach the FY28 EBITDA target.
The capex cycle is reaching its peak in FY25 at approximately Rs. 1,372 crs and is expected to decline in FY26 to around Rs. 1,000 crs as major projects move toward commissioning.
The company is entering a 'taper-down' mode for capital expenditure to improve returns and free cash flow, moving from aggressive building to optimization.
The company is maintaining a high investment intensity with a Capex estimate of approximately ₹ 1000 Cr for FY26 to fuel its roadmap.
Capex intensity is beginning to decelerate as the company moves past the peak of its heavy investment cycle, focusing now on commissioning and cash flow unlocking.
“Considering incremental capex for MMA expansions, PEDA, etc FY26 capex to be ~₹1100 crs, v/s initially planned capex of ₹1000 crs.”
Future Outlook and Roadmap
The company has set an ambitious target to nearly double its EBITDA (earnings before interest, taxes, depreciation, and amortization) over the next three years.
Management maintains its midterm EBITDA growth trajectory, supported by the commissioning of Zone 4 and operational leverage from higher capacity utilization.
The company maintains its ambitious 3-year EBITDA growth target, supported by a 37% YoY increase in Q3 FY26 EBITDA.
Management reaffirmed commitment to FY28 EBITDA aspirations, supported by a 36% Q-o-Q surge in Q2 EBITDA driven by operating leverage.
The company maintains its ambitious 3-year EBITDA target, which requires a CAGR of roughly 25-30% from the FY25 base. Growth is expected to be driven by volume ramp-ups (Rs. 350-550 Cr) and new Capex (Rs. 300-450 Cr).
While FY25 EBITDA was muted at Rs. 1,016 Cr due to competitive pressures, the company is projecting a massive jump to Rs. 1,800-2,200 Cr by FY28, driven by operating leverage from new capacities.
Management reaffirmed their 3-year EBITDA guidance of Rs. 1,800 crore despite a soft Q1, relying on new high-margin products from Zone IV and cost-saving initiatives.
The company has reaffirmed its long-term target to double EBITDA by FY28, supported by volume ramp-ups and cost optimization initiatives.
Management maintains a steady outlook on its 3-year EBITDA target, supported by a 17% overall portfolio volume growth in FY25 and upcoming cost optimizations.
“Target EBITDA range of ₹ 1,800-2,200 Cr in 3 years”
MMA scale up
The company is significantly expanding its MMA (Monoisobutylene) production capacity to meet growing demand in the energy and additives sector.
The company is accelerating its MMA capacity expansion, moving from 290+ KTPA to 360 KTPA with completion expected by Q4FY26 to capture 'swing demand'.
MMA production volumes are accelerating significantly following recent capacity additions, with a further expansion to 360 KTPA currently underway to meet high demand in the energy sector.
The company has achieved peak utilization of newly expanded MMA capacities and is now initiating debottlenecking to further scale volumes by Q4 FY26.
MMA capacity utilization has surged dramatically from 31% in Q2 FY25 to 98% in Q2 FY26, with production volumes tripling year-over-year. Further debottlenecking of 300 KT is fast-tracked for Q4 FY26.
The MMA capacity expansion is progressing from a base of 23.1 KT in FY22 to 123 KT in FY25, with a massive jump to 260 KTPA scheduled for Q1 FY26. This represents a significant step-function growth in production capability.
The company has successfully debottlenecked its MMA capacity from 200 KTPA to 260 KTPA and is seeing immediate volume absorption with record exports in July.
The MMA (Monoisobutylene) expansion to 200 KTPA was completed in Q4 FY25, showing a steady ramp-up in production volumes over the fiscal year.
The MMA (Monoisobutylene) initiative is in a high-growth market development phase with volumes increasing 38% over two years, though utilization remains the primary focus for the next 12-24 months.
“MMA quarterly production driven by increased capacity; Further expansion to 360kT underway”
Zone 4 Development
Aarti is investing heavily in 'Zone 4', a major new production area that will house multiple plants for advanced chemicals using their own internal technology.
Zone 4 projects are entering the final commissioning phase in CY26, representing a major step-function growth platform using indigenous technology.
The Zone-4 expansion is progressing steadily with the Multi-Purpose Plant (MPP) expected to commission in Q4 FY26, followed by gradual block commissioning through FY27.
Zone 4 expansion is progressing with specific commissioning timelines: Calcium Chloride in Q3 FY26, a Multipurpose Plant (MPP) in Q4 FY26, and 5 sequential blocks throughout FY27.
Execution is progressing as per plan with gradual commissioning expected to start from Q3 FY26. Customer engagements for Zone IV products have already been initiated.
The company is moving into a new phase of growth with the commissioning of Multi-Purpose Plants (MPP) and Zone 4 projects targeted for CY26, following the peak capex year of FY25.
Zone IV projects are on track for phased commissioning starting H2 FY26, with the first phase (MPP and Calcium Chloride) expected by December 2025.
The company has initiated execution for Multi-Purpose Plants (MPP) and Zone 4, with commissioning expected to drive growth between FY26 and FY28.
Zone 4 is the primary driver of future growth with staggered commissioning starting in Q3 FY26; however, significant volume contributions are back-ended to FY27.
“The total CAPEX on Zone 4 would be in the range of INR1,600 crore to INR1,800 crore. Bulk of that would be deployed by the end of this year... With Zone IV getting commercialised in CY26”
DCB Debottlenecking
The company is increasing its production capacity for DCB (a chemical used in high-performance plastics) to capture more market opportunities.
DCB production is showing a steady upward trajectory in volume, supported by debottlenecking efforts to reach 140 KTPA to meet downstream demand.
DCB volumes showed a strong recovery in Q2 FY26 (up 14% QoQ) after a dip in Q1, supported by downstream demand. Management expects this strength to continue through H2.
DCB production has shown steady volume growth over four years, increasing from 74.6 KT in FY22 to 88.6 KT in FY25, with a current capacity of 120 KTPA and further ramp-up planned.
While capacity is ready, DCB volumes saw a sharp decline this quarter due to US inventory liquidation and automotive demand uncertainty, though recovery is expected in H2.
DCB production volumes have remained relatively stable throughout FY25, with a slight decline in the final quarter, though overall FY25 utilization reached 74%.
“We have also started debottlenecking efforts to increase DCB capacity from 120 to 140 KTPA to capture incremental growth opportunities in this (DCB) segment.”
PEDA (ethylation downstream) commissioning
Aarti is investing in a new downstream project (PEDA) to integrate its ethylation products, which is expected to improve profit margins and capacity use.
“PEDA (ethylation downstream) commissioning in Q4FY26.”
DCB chain debottlenecking
Aarti is expanding its DCB (Dichlorobenzene) chain capacity through debottlenecking to capture higher demand from downstream customers.
Debottlenecking of DCB capacity is underway to capture incremental growth, particularly in the EV segment via PPS growth.
“DCB volumes increase supported by PDCB and downstream demand; further capacity debottlenecking to 140kT underway”
US Export Resumption
The company is seeing a strong recovery in export volumes to the US for key products like MMA and PDCB after previous tariff-related disruptions.
“MMA and PDCB US exports resumed in Q3”
Advanced Materials Strategy
Aarti is shifting its focus toward 'Advanced Materials'—high-value chemicals tailored for specific uses—to move away from lower-margin bulk products.
“Our future growth strategy is now decisively anchored in the Advanced Materials space. We are pivoting from bulk products toward high-value, application-led solutions.”
Chemical Recycling of plastics (reaarti)
Aarti is entering the sustainable materials market through a joint venture focused on the chemical recycling of plastics.
“Chemical Recycling of plastics... Expected commissioning in H1FY27”
EBITDA Margin Recovery
China's new policy to stop 'dumping' chemicals at low prices is expected to help Aarti recover its profit margins as global prices stabilize.
“As China prioritizes higher-quality growth and enforces stricter supply-side discipline, we anticipate a more rational global pricing environment... this transition could serve as a structural catalyst for sustainable margin recovery.”
Operational Efficiency via AI
The company is using Artificial Intelligence (AI) across its factories to improve efficiency, reduce energy use, and lower production costs.
“we have initiated the deployment of AI and digital transformation tools across our manufacturing plants... to achieve measurable gains in plant uptime and a reduction in energy consumption.”
Cost Optimisation
Aarti is implementing cost-saving measures, including switching to more efficient power turbines and using renewable energy, to boost profitability.
“Cost Optimisation ₹ 150-200 crore... Switching to Back Pressure Turbine to improve Cogen, Renewable Power phase 2”
Superform Joint Venture
A new joint venture with 'Superform' is set to begin production soon, targeting the agrochemical and paint industries to diversify the company's customer base.
“The Joint Venture with Superform is progressing well, with commissioning expected in Q1FY27, focusing on agrochemical, paints and coatings applications”
Exclusive distributor agreement with Actylis for PCBTF
The company is expanding its reach in North America through a new 3-year exclusive distribution deal for a specific chemical used in agrochemicals.
“Entered into 3 yr strategic exclusive distributor agreement with Actylis for supply of PCBTF (part of Chloro Toluene Value chain) in North American market.”
Chinese Dumping Pressure
Persistent 'dumping' (selling at unfairly low prices) by Chinese competitors continues to keep prices low in the Agrochemical and Pharmaceutical sectors, limiting profit growth.
“Agrochemicals and Pharmaceuticals continue to see stable volumes, but pricing remained subdued due to persistent dumping by China.”
Dyes & Pigments Market Condition
Growth in the Dyes and Pigments segment is currently limited by low demand and pricing pressure from international competition.
“Muted demand growth in downstream markets with US tariffs impacting some applications; Pricing pressure continues to prevail”
CAPACITY_EXPANSION (current: 290+ KTPA -> 360 KTPA), by Underway — MMA production capacity
The MMA capacity expansion is progressing from a base of 23.1 KT in FY22 to 123 KT in FY25, with a massive jump to 260 KTPA scheduled for Q1 FY26. This represents a significant step-function growth in production capability.
“MMA capacity expansion to 260 kT completed (from Q1 FY26)”
The company is accelerating its MMA capacity expansion, moving from 290+ KTPA to 360 KTPA with completion expected by Q4FY26 to capture 'swing demand'.
MMA production volumes are accelerating significantly following recent capacity additions, with a further expansion to 360 KTPA currently underway to meet high demand in the energy sector.
The company has achieved peak utilization of newly expanded MMA capacities and is now initiating debottlenecking to further scale volumes by Q4 FY26.
MMA capacity utilization has surged dramatically from 31% in Q2 FY25 to 98% in Q2 FY26, with production volumes tripling year-over-year. Further debottlenecking of 300 KT is fast-tracked for Q4 FY26.
The company has successfully debottlenecked its MMA capacity from 200 KTPA to 260 KTPA and is seeing immediate volume absorption with record exports in July.
The MMA (Monoisobutylene) expansion to 200 KTPA was completed in Q4 FY25, showing a steady ramp-up in production volumes over the fiscal year.
The MMA (Monoisobutylene) initiative is in a high-growth market development phase with volumes increasing 38% over two years, though utilization remains the primary focus for the next 12-24 months.
CAPACITY_EXPANSION -> Multiple process blocks (MPP, Chloro toluene) in Zone 4
Zone 4 expansion is progressing with specific commissioning timelines: Calcium Chloride in Q3 FY26, a Multipurpose Plant (MPP) in Q4 FY26, and 5 sequential blocks throughout FY27.
“In the next quarter, we are commissioning our multipurpose plant, both of these are at Zone 4... Post that, there are 5 blocks, incremental blocks in Zone 4. I think each of the blocks will get sort of sequentially commissioned throughout the next financial year.”
Zone 4 projects are entering the final commissioning phase in CY26, representing a major step-function growth platform using indigenous technology.
The Zone-4 expansion is progressing steadily with the Multi-Purpose Plant (MPP) expected to commission in Q4 FY26, followed by gradual block commissioning through FY27.
Execution is progressing as per plan with gradual commissioning expected to start from Q3 FY26. Customer engagements for Zone IV products have already been initiated.
The company is moving into a new phase of growth with the commissioning of Multi-Purpose Plants (MPP) and Zone 4 projects targeted for CY26, following the peak capex year of FY25.
Zone IV projects are on track for phased commissioning starting H2 FY26, with the first phase (MPP and Calcium Chloride) expected by December 2025.
The company has initiated execution for Multi-Purpose Plants (MPP) and Zone 4, with commissioning expected to drive growth between FY26 and FY28.
Zone 4 is the primary driver of future growth with staggered commissioning starting in Q3 FY26; however, significant volume contributions are back-ended to FY27.
CAPACITY_EXPANSION (current: 120 KTPA -> 140 KTPA), by FY26 — DCB production
DCB production volumes have remained relatively stable throughout FY25, with a slight decline in the final quarter, though overall FY25 utilization reached 74%.
“DCB Capacity 120 KTPA... FY25 Utilization% 74%”
DCB production is showing a steady upward trajectory in volume, supported by debottlenecking efforts to reach 140 KTPA to meet downstream demand.
DCB volumes showed a strong recovery in Q2 FY26 (up 14% QoQ) after a dip in Q1, supported by downstream demand. Management expects this strength to continue through H2.
DCB production has shown steady volume growth over four years, increasing from 74.6 KT in FY22 to 88.6 KT in FY25, with a current capacity of 120 KTPA and further ramp-up planned.
While capacity is ready, DCB volumes saw a sharp decline this quarter due to US inventory liquidation and automotive demand uncertainty, though recovery is expected in H2.
REVENUE_DRIVER: Export Revenue Share
Export volumes are recovering, particularly in the Energy and Polymer segments, with 85% of Energy and 92% of Polymer/Additives revenue coming from exports.
“Revenue increased due to: Higher volumes across various products... MMA and PDCB US exports resumed in Q3”
Export share has reached a record high of 65%, showing an accelerating trend in global market penetration despite geopolitical volatility.
Export share remains high at upwards of 60%, though the company is actively rebalancing the mix away from the U.S. toward Europe and the Middle East due to tariff headwinds.
Export volumes grew by approximately 17% in FY25, indicating strong global traction and successful positioning in international markets.
Export revenue faced temporary headwinds from geopolitical conflicts (Israel-Iran and India-Pak) and logistics delays, leading to a deferment of Rs. 15-20 crore EBITDA to Q2.
Export traction is accelerating in specific segments like Energy & Additives (80% export) and Polymer & Additives (92% export), with a focus on diversifying the geographic base.
Export share is accelerating, reaching 55% in the most recent quarter, driven by a recovery in global shipments and strategic diversification into the US and Europe.
REVENUE_DRIVER: Target EBITDA = Rs. 1,800-2,200 Cr
The company maintains its ambitious 3-year EBITDA growth target, supported by a 37% YoY increase in Q3 FY26 EBITDA.
“Target EBITDA range of ₹ 1,800-2,200 Cr in 3 years”
Management maintains its midterm EBITDA growth trajectory, supported by the commissioning of Zone 4 and operational leverage from higher capacity utilization.
Management reaffirmed commitment to FY28 EBITDA aspirations, supported by a 36% Q-o-Q surge in Q2 EBITDA driven by operating leverage.
The company maintains its ambitious 3-year EBITDA target, which requires a CAGR of roughly 25-30% from the FY25 base. Growth is expected to be driven by volume ramp-ups (Rs. 350-550 Cr) and new Capex (Rs. 300-450 Cr).
While FY25 EBITDA was muted at Rs. 1,016 Cr due to competitive pressures, the company is projecting a massive jump to Rs. 1,800-2,200 Cr by FY28, driven by operating leverage from new capacities.
Management reaffirmed their 3-year EBITDA guidance of Rs. 1,800 crore despite a soft Q1, relying on new high-margin products from Zone IV and cost-saving initiatives.
The company has reaffirmed its long-term target to double EBITDA by FY28, supported by volume ramp-ups and cost optimization initiatives.
Management maintains a steady outlook on its 3-year EBITDA target, supported by a 17% overall portfolio volume growth in FY25 and upcoming cost optimizations.
CAPACITY_EXPANSION (current: 120 KTPA -> 140 KTPA) for DCB
Debottlenecking of DCB capacity is underway to capture incremental growth, particularly in the EV segment via PPS growth.
“We have also started debottlenecking efforts to increase DCB capacity from 120 to 140 KTPA to capture incremental growth opportunities in this (DCB) segment.”
REVENUE_DRIVER: Annual Capex = ~Rs. 1100 crs
The capex cycle is reaching its peak in FY25 at approximately Rs. 1,372 crs and is expected to decline in FY26 to around Rs. 1,000 crs as major projects move toward commissioning.
“Capex for FY26 estimated to be around ₹ 1000 Cr; Capex cycle at its peak in FY25”
Capex has been revised upward from Rs. 1,000 crs to Rs. 1,100 crs to fast-track high-return projects like MMA and DCB debottlenecking.
Capex intensity is accelerating as the company increases its FY26 budget to Rs. 1100 crore to fast-track MMA and PEDA expansions.
The company is maintaining its FY26 capex guidance of Rs. 1,000 crore but signals a significant reduction in spending for FY27 as the current cycle concludes.
Capex remains aggressive at approximately Rs. 1000 Cr for FY26 to drive the next 3 years of volume growth. This represents a high investment intensity to reach the FY28 EBITDA target.
The company is entering a 'taper-down' mode for capital expenditure to improve returns and free cash flow, moving from aggressive building to optimization.
The company is maintaining a high investment intensity with a Capex estimate of approximately ₹ 1000 Cr for FY26 to fuel its roadmap.
Capex intensity is beginning to decelerate as the company moves past the peak of its heavy investment cycle, focusing now on commissioning and cash flow unlocking.
REVENUE_DRIVER: U.S. Export Volume (Tariff Impact)
U.S. tariffs caused a significant volume drop in Q2, but management expects a resumption of volumes in Q3 despite ongoing uncertainty.
“Our share of U.S. business in the last quarter was significantly lower compared to Q1. So there was definitely a pain. It was offset by a push in the other geographies.”
The US-India trade deal is a major positive inflection point, reversing the headwind of high tariffs and expected to significantly improve margins and volumes.
US export volumes for key products like MMA and PDCB have resumed in Q3 FY26, though full recovery remains linked to future trade deals.
US tariffs are currently a significant headwind, negatively impacting volumes in the PDA and Polymer/Additives segments. Recovery is explicitly linked to a potential US-India trade deal.
The US tariff actions against China are creating an immediate positive tailwind for specific chains like PDA (MPD), leading to higher anticipated utilization.
MODERATE risk • 17 risks identified ·
Aarti is undergoing a massive expansion phase (Zone 4) which carries the risk of slow profit ramp-up as new products must go through long approval cycles with customers.
2-year time frame for meaningful ramp-up
The risk is STABLE as the company confirms that major projects like Zone 4 and the UPL JV are still in the commissioning/ramp-up phase with targets for CY26, confirming the long lead times previously identified.
Utilizing Multi-Purpose Plants (MPP) to support quick development and qualification of new advanced chemistries.
Demand for DCB (used in polymers for auto) was significantly lower due to U.S. customer inventory liquidation and automotive sector uncertainty.
Management relies on annual contracts and expects volume recovery in the second half as inventory corrections conclude.
Execution risk is active as the company enters the commissioning phase for multiple plants. Management acknowledged that specialty products from Zone 4 will take time to ramp up due to customer qualification cycles.
Sequential commissioning of 5 blocks throughout the next financial year to manage the ramp-up; focus on 'medium-ticket' projects that utilize existing infrastructure for faster turnaround.
The risk is stable as the company enters the commissioning phase for Zone 4. Management confirmed a 2-year timeframe for meaningful utilization ramp-up in specialty blocks due to these qualification cycles.
Phased commissioning of process blocks and using in-house technology to ensure flexible asset utilization.
The risk is intensifying for the PDA chain specifically, with capacity utilization dropping to 43% and a 28% decline in volumes quarter-over-quarter.
Linking improvement to the potential US-India trade deal and diversifying PDCB demand into other markets including China.
Persistent dumping of chemicals by China at low prices continues to depress profit margins in the Agrochemicals and Pharmaceuticals segments.
The risk remains intensifying in terms of pricing. While volumes are recovering, overcapacity in China leads to 'marginal pricing' (selling at very low prices to cover basic costs), preventing an uptick in margins despite the end of destocking.
Focusing on cost optimization initiatives (variable and fixed) and yield improvements in key chains like Ammonolysis and NCB to maintain competitiveness.
The risk remains high and stable; while management sees 'stray incidences' of price realizations improving, they do not yet see a firm trend of Chinese competitive intensity turning around.
Focusing on cost optimization and efficiency to survive at current price levels and gain market share when the cycle turns.
Competitive pressure from China remains intense, specifically affecting margins in the ethylation and fluoro chain products. Agrochemical margins remain under pressure despite steady volumes.
Pursuing variable cost optimization projects in fluoro chain products and targeting margin growth through operating leverage.
The risk is showing signs of easing due to China's 'anti-involution' strategy and the removal of VAT export rebates (e.g., 13% removal on NCB chain), which has already led to a 7-10% price increase in certain product lines.
Focus on integrated, quality-focused manufacturing and leveraging in-house R&D to remain a low-cost producer.
High spending on new factories and projects has led to a slight increase in debt and the cost of paying interest on that debt.
CAPEX for the year estimated to be about Rs. 1,100 crs
The risk is intensifying slightly as the FY26 CAPEX guidance was raised from Rs. 1,000 crs to Rs. 1,100 crs. This has already resulted in a marginal increase in debt and interest costs during Q3.
Management anticipates significantly lower CAPEX for FY27 as major projects like Zone 4 conclude.
The risk is intensifying as the FY26 Capex estimate has been revised upward to ~Rs. 1100 crs from the initial Rs. 1000 crs, and working capital needs have increased debt.
Targeting a Debt/EBITDA of <2.5x and ROCE of >15% within 3 years through volume and margin ramp-up.
The risk is easing as management believes net debt has 'peaked out' at Rs. 3,500 crore. Capex is projected to decrease from Rs. 1,372 cr in FY25 to Rs. 950-1000 cr in FY26, with a target to reduce debt by Rs. 200-300 crore.
Reducing CAPEX intensity and focusing on unlocking cash flow from working capital.
Interest costs have increased significantly from Rs 211 crs to Rs 275 crs. However, the trajectory is shifting to EASING as management states the capex cycle peaked in FY25 and will decline progressively in FY26 and FY27.
Reducing incremental capex and optimizing working capital from 85 days to 60 days to improve cash flow.
The risk is easing as the company enters a 'taper-down mode' for Capex, with spending expected to drop from Rs. 1,300-1,400 crore last year to below Rs. 1,000 crore in FY26 and further in FY27.
Stringent capital allocation criteria and a commitment to reduce net debt by Rs. 200-300 crore in FY26.
Profitability is being squeezed in the agrochemicals and dyes segments due to ongoing pricing pressures and high input costs.
Margins were severely impacted this quarter by a 15-20% drop in key input prices (benzene/aniline), leading to Rs. 30 crore in inventory valuation losses.
Implementing cost-saving initiatives like renewable power purchase and yield improvements expected to contribute Rs. 150-200 crore to EBITDA.
Margins remain under pressure across most product portfolios. Management is pivoting toward aggressive cost optimization to offset this, targeting Rs. 150-200 crore in savings.
Implementing cost optimization initiatives including switching to Back Pressure Turbines, renewable power, and yield improvements.
The risk remains intensifying as margins in the agro and dyes segments are still under pressure due to Chinese competition and pricing pressures.
Targeting higher share in the domestic market and pursuing variable cost optimization projects in the fluoro chain.
The risk remains high as management explicitly states that the Agrochemicals sector continues to be under pressure and pricing pressures persist across various product chains, despite volume upticks in other areas.
Management is implementing variable and fixed cost optimization initiatives, including yield improvements and process optimization, to tackle pricing pressure.
The risk remains high as management explicitly notes that the competitive landscape is causing margin contractions despite volume growth. Intermediates for the Agrochemical sector specifically continue to be 'under pressure'.
Focusing on cost optimization initiatives (BPT project, hybrid power) and yield improvements to protect margins.
The company relies heavily on exports, which increases its vulnerability to global shipping delays and requires more money to be tied up in day-to-day operations (working capital).
Exports constituted about 65% of total revenues
The risk is intensifying in the short term due to higher freight costs. Exports rose to 55% of revenue, which increased 'other expenses' due to the freight component. However, working capital days are being managed toward a 70-80 day target.
Implementing cost optimization for fixed costs and managing inventory valuations to offset freight spikes.
The risk is intensifying as the U.S. announced a new 25% tariff on Indian imports plus an unspecified 'penalty,' creating significant market uncertainty for products that account for 15-20% of revenue.
Management is assessing potential impact, exploring alternate ways to scale volumes outside the U.S., and developing new global markets including Europe.
Logistics risks intensified this quarter due to the Israel-Iran conflict and India-Pakistan tensions, causing shipment delays, rerouting, and an EBITDA deferment of Rs. 15-20 crore.
Management is optimizing inventory levels and rerouting shipments to navigate regional disruptions.
The risk is intensifying as non-energy volumes were specifically impacted by delays in bulk shipments during Q3.
Diversifying demand growth across various markets including China and onboarding multiple O&G majors in Europe and Africa.
The risk is easing as the company sees positive demand traction in products like MPD (PDA chain) where they have a clear advantage over Chinese competitors who are now hit by tariffs. Management expects the tariff situation to bring clarity to trade flows within 2-4 months.
Aggressive market development to expand the customer base and geographic reach (US, Europe, India) to diversify away from concentrated regions.
The company faces significant exposure to U.S. trade policy, with major products like MMA, PDCB, and NCB previously subject to high tariffs which impacted volumes and margins.
Tariffs reduced from 50% plus to 18% plus
The risk is transitioning into a potential opportunity. Management notes that the US tariff situation on China may create new market opportunities for Indian exports due to tariff differentials.
Strategic efforts to diversify customer and geography base are in progress to leverage tariff differentials.
The company is heavily dependent on a single product line, MMA, for a large portion of its export earnings, making it vulnerable to price swings in that specific market.
MMA constitutes 50% to 60% of U.S. export contribution
MMA achieved highest-ever quarterly volumes, but the company is actively working to reduce this concentration. Management expects energy-linked products to settle at 30-40% of the mix as new specialty blocks come online.
Commissioning 5 new blocks in Zone 4 and a PEDA project to increase the share of Agrochemical and Polymer applications.
Execution risk is being managed with Zone-4 projects progressing as per plan. A key milestone was achieved by securing a long-term chlorine supply agreement to support this facility.
Signed a long-term strategic supply agreement with DCM Shriram to secure chlorine supply via a dedicated pipeline for the Zone-IV facility.
The Polymers segment faces demand and pricing pressure due to its heavy reliance on the U.S. market for specific product chains like PDA.
The risk is easing following the U.S.-India trade deal. Management expects utilization for the PDA chain to improve as conversations with the two largest U.S. customers resume under the new tariff regime.
Debottlenecking DCB capacity to capture growth in the EV segment (PPS) to offset PDA volatility.
Profitability is being squeezed in the agrochemicals and dyes segments due to ongoing pricing pressures and high input costs.
The risk is stable as pricing pressures persist, but management is aggressively pursuing cost-efficiency projects. EBITDA for FY25 (₹ 1016 Cr) was at the lower end of the projected range, confirming the squeeze.
Implementation of Back-Pressure Turbine projects, Hybrid Power, and yield improvements to drive cost savings.
While pricing pressure persists, the company is successfully using 'operating leverage' (spreading fixed costs over higher production volumes) to boost EBITDA, which rose 36% Q-o-Q.
Implementing a Rs. 150-200 crore cost-optimization program, including renewable power purchase agreements and raw material contract renegotiations.
Persistent dumping of chemicals by China at low prices continues to depress profit margins in the Agrochemicals and Pharmaceuticals segments.
The risk remains intensifying in terms of pricing. While volumes are recovering, overcapacity in China leads to 'marginal pricing' (selling at very low prices to cover basic costs), preventing an uptick in margins despite the end of destocking.
Focusing on cost optimization initiatives (variable and fixed) and yield improvements in key chains like Ammonolysis and NCB to maintain competitiveness.
The risk remains high and stable; while management sees 'stray incidences' of price realizations improving, they do not yet see a firm trend of Chinese competitive intensity turning around.
Focusing on cost optimization and efficiency to survive at current price levels and gain market share when the cycle turns.
Competitive pressure from China remains intense, specifically affecting margins in the ethylation and fluoro chain products. Agrochemical margins remain under pressure despite steady volumes.
Pursuing variable cost optimization projects in fluoro chain products and targeting margin growth through operating leverage.
The risk is showing signs of easing due to China's 'anti-involution' strategy and the removal of VAT export rebates (e.g., 13% removal on NCB chain), which has already led to a 7-10% price increase in certain product lines.
Focus on integrated, quality-focused manufacturing and leveraging in-house R&D to remain a low-cost producer.
| Risk | May 2025 | Aug 2025 | Nov 2025 | Feb 2026 |
|---|---|---|---|---|
The company faces significant exposure to U.S. trade policy, with major produ... HIGH Regulatory | ||||
Persistent dumping of chemicals by China at low prices continues to depress p... HIGH Competitive | ||||
The company is heavily dependent on a single product line, MMA, for a large p... HIGH Concentration | ||||
The company relies heavily on exports, which increases its vulnerability to g... MEDIUM Concentration | — | |||
Aarti is undergoing a massive expansion phase (Zone 4) which carries the risk... MEDIUM Execution | ||||
High spending on new factories and projects has led to a slight increase in d... MEDIUM Balance Sheet | ||||
The Polymers segment faces demand and pricing pressure due to its heavy relia... MEDIUM Demand | — | — | ||
Profitability is being squeezed in the agrochemicals and dyes segments due to... MEDIUM Margin & Cost | — |
